CD274 and neoplasm: Pembrolizumab-containing treatment is currently prescribed as a non-personalized first-line treatment, since it has been approved for all advanced NSCLC patients who lack targetable driver mutations regardless of their tumour PD-L1 expression (Reck et al., 2019; Gadgeel et al., 2020).